A b s t r a c t
Cervical intraepithelial neoplasia grade 3 (CIN 3) is the best proxy in research and screening for invasive cancer risk. Yet the timing of CIN 3 development is uncertain because of measurement errors integral to its diagnosis. We were interested in estimating the proportions of prevalent vs incident CIN 3 within 2 years of finding a minor cytologic abnormality. We estimate that only 17 (2.8%) of 613 CIN 3 cases diagnosed during the 2-year duration of the atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesion (LSIL) triage study (ALTS) were incident CIN 3 following an incident human papillomavirus (HPV) infection that persisted until the CIN 3 diagnosis was made. Using prevalent high-grade cytology as a marker of prevalent CIN 3, we estimated that another approximately 23% of CIN 3 cases were incident CIN 3 following a prevalently detected HPV infection that persisted until the CIN 3 diagnosis was made. We concluded that most CIN 3 cases diagnosed within the 2-year time frame were prevalent cases, and most incident CIN 3 cases followed a prevalently detected HPV infection.
Cervical intraepithelial neoplasia grade 3 (CIN 3), including carcinoma in situ, is the immediate precursor to invasive cervical cancer and therefore considered the most scientifically rigorous definition of cervical precancer. 1 However, very little is known about the natural history of CIN 3 for obvious ethical reasons. In one study in which treatment was withheld from women diagnosed with CIN 3, approximately one third of them developed invasive cervical cancer in the following 30 years. 2 Of note, these women were approximately 10 years older at the time of CIN 3 diagnosis than the median age of women diagnosed with CIN 3 in current, routine screening. 3 This suggests that these untreated cases of CIN 3 may have involved larger, more mature lesions than the typical CIN 3 cases found on routine screening, and therefore are more likely to have invasive potential. 4 To understand CIN 3 and its early natural history, we embarked on a descriptive analysis to compare prevalent vs incident CIN 3 identified in the atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesion (LSIL) triage study (ALTS), a randomized trial to compare management strategies for women with equivocal and mildly abnormal findings on Papanicolaou (Pap) tests. Presumably, incident CIN 3 has the least invasive potential because it is newly developed and small but then over time develops into a larger CIN 3 with invasive potential. 4, 5 In particular, because of errors in the diagnostic process (particularly colposcopic insensitivity), it is often challenging to differentiate between missed prevalent vs truly incident CIN 3 among human papillomavirus (HPV)-positive women who are subsequently diagnosed with CIN 3. Using data from ALTS, we can begin to learn about the early natural history of CIN 3, which is expected to include small lesions with low-invasive potential found in young women with mild cytologic abnormalities.
Why is it important to differentiate between prevalent and incident CIN 3? Most studies have focused on prevalent CIN 3, and therefore, the timing and determinants of new CIN 3 is poorly understood. More importantly, understanding the timing and evolution of CIN 3 will help predict the effect of interventions. (1997) (1998) (1999) (2000) (2001) ) was a multisite, randomized clinical trial comparing 3 management strategies (immediate colposcopy [IC], HPV triage, or conservative management [CM]) for women referred for ASCUS (n = 3,488) or LSIL (n = 1,572) conventional cytology. [6] [7] [8] [9] [10] The ASCUS category under the 1991 Bethesda System 11 used in ALTS was slightly more inclusive, particularly of probable reactive changes and atypical squamous cells, cannot rule out high-grade intraepithelial lesion (ASC-H), than ASC-US under the 2001 Bethesda system. 12 All women in the IC arm underwent colposcopy at enrollment. Women in the HPV arm underwent colposcopy if they tested positive to carcinogenic HPV with the Hybrid Capture 2 (HC2, Qiagen, Gaithersburg, MD) test or had highgrade squamous intraepithelial lesion (HSIL) on cytologic testing at enrollment. Women in the CM arm underwent colposcopy if they had HSIL on cytologic testing at enrollment. The National Cancer Institute and local institutional review boards approved the study and all participants provided written, informed consent.
Materials and Methods

Study Design and Population
ALTS
At enrollment and follow-up visits over the 2-year duration, all women underwent a pelvic examination with collection of 2 cervical specimens; the first specimen in PreservCyt for ThinPrep cytology (Cytyc Corporation, Marlborough, MA; now Hologic) and the second in specimen transport medium (Digene Corporation, Gaithersburg, MD; now Qiagen). Women in all 3 arms of the study underwent cytologic reevaluation every 6 months during the 2 years and had a colposcopy if the cytologic finding was HSIL. An exit examination with colposcopy was scheduled for all women. Details on randomization, examination procedures, patient management, and laboratory and pathology methods were published previously. [6] [7] [8] [9] [10] 
HPV DNA Testing
Line blot assay (LBA) for the detection of 27 or 38 individual HPV genotypes and linear array for detection of 37 of 38 HPV genotypes detected with LBA (excluding HPV57) were conducted on all archived specimen transport medium specimens from women diagnosed with CIN 3. [13] [14] [15] [16] The results of the 2 tests were combined to maximize analytic sensitivity and more accurately describe the natural history of CIN 3. Of the 621 CIN 3 cases diagnosed during the 2-year duration of ALTS by the clinical center (CC) or the quality control (QC) pathology groups, 17 613 underwent at least LBA or linear array testing at enrollment and diagnosis. HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68, the types targeted by HC2, were defined as the carcinogenic HPV genotypes. 18 HPV26, 53, 66, 67, 70, 73, and 82 were defined as borderline carcinogenic HPV genotypes, HPV genotypes that cause CIN 3 but are very unlikely to cause cervical cancer. 18, 19 Other HPV genotypes were classified as noncarcinogenic. HPV results were categorized hierarchically according to cancer risk (HPV risk groups) as carcinogenic > borderline carcinogenic > noncarcinogenic> HPV negative.
Of the 613 CIN 3 cases that had polymerase chain reaction (PCR) results, 584 (95.3%) also had HC2 results; HC2-positive results were used as appropriate to reclassify enrollment HPV status: (1) 25 women went from incident, persistent carcinogenic HPV infection to prevalent, persistent carcinogenic HPV (ie, we assumed that the causal type was present at enrollment because HC2 was already positive, but that type was missed by PCR); (2) 1 woman went from incident, persistent borderline carcinogenic HPV infection to prevalent, persistent borderline carcinogenic HPV (because HC2 cross-reacts with these borderline carcinogenic HPV genotypes); and (3) 1 woman went from HPV-negative prevalent CIN 3 to carcinogenic HPV-positive prevalent CIN 3.
Statistical Analyses
We divided CIN 3 into 4 categories: (I) "prevalent" if found at enrollment; (II) "incident CIN 3 following prevalent, persistent HPV" if at least 1 HPV infection was detected at enrollment and persisted until the time of the incident CIN 3 diagnosis after enrollment; (III) "incident CIN 3 following incident, persistent HPV" if at least 1 HPV infection was detected after enrollment and persisted until the time of the incident CIN 3 diagnosis after enrollment; and (IV) "incident CIN 3, no persistence" if an incident CIN 3 was not preceded by measurable persistent HPV infection. We defined persistence for a specific HPV genotype as being positive for the screening visit leading to colposcopic referral and diagnosis and at least at 1 additional preceding visit.
We stratified categories of CIN 3 by HPV risk groups and by study arm to estimate the proportions of each CIN 3 category, recognizing that differences in the treatment of women at enrollment would affect these distributions.
Fisher exact test was used to test for differences in distributions. P values of < .05 were considered statistically significant. Stata software version 11.0 (Stata, College Station, TX) was used for statistical analyses.
Results
The baseline characteristics of women in ALTS with a CIN 3 diagnosis are shown in ❚Table 1❚. Approximately half were smokers, most (63%) were using oral contraceptives, and most women had been pregnant at least once (72%) and had at least 1 live birth (59%). The majority (69%) of the women with CIN 3 were white. Their median, mean, interquartile range, and range of ages at enrollment were 23, 24.9, 21-27, and 18-70 years, respectively.
❚Table 2❚ shows the distribution of CIN 3 diagnoses by study arm, timing of diagnosis (prevalent vs incident), timing and duration of HPV detection (prevalent vs incident; persistent vs no persistence), and HPV risk group. There were fewer cases of CIN 3 in the HPV arm of the trial because for women referred to ALTS for an LSIL finding on Pap test, an HPV testing was deemed not useful for deciding who needed immediate colposcopy; this part of the trial was halted before enrollment was completed. 7 Of the 613 cases of CIN 3 included in this analysis, we attributed 95.1% to carcinogenic HPV, 2.3% to borderline carcinogenic HPV, 1.5% to noncarcinogenic HPV, and 1.1% tested HPV negative.
The notable difference between study arms was that the percentage of prevalent CIN 3 found at enrollment was less in the CM arm compared with the IC and HPV arm (35.7% vs 61.6% and 66.9%, respectively, P < .001, Fisher exact test) because of the differences in the sensitivity of the management strategies by arm. As a consequence, the percentage of incident CIN 3 following a prevalent, persistent HPV infection was greater in the CM arm compared with the IC and HPV arms (60.2% vs 31.9% and 28.8%, respectively, P < .001, Fisher exact test), evidence of the insensitivity of the CM arm, which only referred women to colposcopy with an HSIL found on cytologic test at enrollment. The fraction of women with incident CIN 3 following incident HPV persistence, the group more certain to have had incident CIN 3, did not vary significantly between study arms (3.1% for IC, 1.8% for HPV, and 1.8% for CM) (P = .4, Fisher exact test). Combining across arms, 2.8% (binomial 95% confidence interval, 1.6%-4.4%) had incident CIN 3 following incident, type-specific persistent HPV infection.
We then examined clinical characteristics at enrollment and at the time of diagnosis across CIN 3 categories, restricting this and subsequent analyses to the IC and HPV arms because of the aforementioned lack of sensitivity of the CM arm. We also excluded cases that that were not detected at baseline and did not follow persistent HPV because of concern that diagnosis was due to misclassification ❚Table 3❚. We noted that the enrollment characteristics for CIN 3 following prevalent, persistent HPV were intermediate to those for prevalent CIN 3 and CIN 3 following incident, persistent HPV but more closely resembled the characteristics of the latter. For example, the proportions of women with a high-grade cytology (HSIL or ASC-H) at enrollment as read by the CC pathologists were 53.6%, 15.0%, and 0.0% for prevalent CIN 3; CIN 3 following prevalent, persistent HPV; and CIN 3 following incident, persistent HPV, respectively (P < .001).
Conversely, the same characteristics at the time of diagnosis for CIN 3 following prevalent, persistent HPV and prevalent CIN 3 were similar to and different from CIN 3 following incident, persistent HPV. The proportions of women with a high-grade cytology at the time of diagnosis as read by the CC pathologists were 53.6%, 51.7%, and 30.8% for prevalent CIN 3; CIN 3 following prevalent, persistent HPV; and CIN 3 following incident, persistent HPV, respectively (P = .3). These data provided indirect evidence that the CIN 3 following prevalent, persistent HPV infections were primarily incident CIN 3 (ie, there was a significant increase in highgrade cytology from the baseline to the time of diagnosis), but a small proportion were prevalent CIN 3 undiagnosed at enrollment.
Because enrollment high-grade cytology was most strongly associated with the different CIN 3 groups, we used it to estimate the proportion of CIN 3 in the "incident CIN 3 following prevalent HPV persistence" category that was missed prevalent vs incident CIN 3. We assumed that the proportion of missed prevalent CIN 3 (found after enrollment) Using the CC pathology interpretation of high-grade cytology and combining data from the IC and HPV arms, we estimated that 28.0% of the incident CIN 3 following prevalent HPV persistence were missed prevalent cases. For reference, using high-grade colposcopic impression, we estimated that 32.6% were missed prevalent cases. Thus, of all 383 cases of CIN 3 diagnosed in the IC and HPV arms (excluding the 9 incident cases that were not preceded by persistent HPV), approximately 25.8% of CIN 3 (n = 99) (estimates based on high-grade cytology as read by CC pathology) or 26.6% of CIN 3 (n = 102) (estimates based on high-grade cytology as read by QC pathology) diagnosed in ALTS were probably with incident disease, most of which followed a persistent HPV infection detected at baseline.
Discussion
Overall, 3% of the CIN 3 cases found in ALTS were almost certainly incident cases because the probable causal persistent HPV infection was detected after enrollment but we cannot completely rule out misclassification of disease or HPV detection. A larger fraction of probably incident disease was found among the women with persistent HPV infection detected at baseline. However, the challenge is differentiating the missed prevalent vs incident CIN 3 in this group because of the known limitations of colposcopy. 20, 21 We illustrated this point indirectly by showing that the number of incident CIN 3 following a prevalent, persistent HPV infection depended on the sensitivity of the management arm.
When we used high-grade cytology as a specific marker for prevalent CIN 3 among women with prevalent HPV and incident CIN 3, we estimated that approximately 25% of all CIN 3 diagnosed in the 2-year span of ALTS could be incident, with almost 90% of the incident CIN 3 found in women who were already HPV positive at enrollment, and their HPV infection persisted until a CIN 3 lesion was identified.
The strength of this study was the rigorous follow-up and good disease ascertainment, including offering all women colposcopy at the exit visit from the trial. The disadvantage is that we only had women referred to the study for a Pap smear finding of an ASCUS or LSIL. Yet a large proportion of high-grade disease is found in women who have ASCUS or LSIL cytology. 22, 23 In conclusion, most of the CIN 3 diagnosed over the 2-year duration of ALTS was carcinogenic HPV positive at baseline and prevalent. At a single time point, carcinogenic HPV detection identified the majority of women who had or would develop CIN 3 in the next 2 years; small proportions of CIN 3 either followed an incident HPV infection because of noncarcinogenic HPV genotypes or were misclassified cases. The results of this analysis have important implications for estimating the effect of interventions targeting HPV infection and/or CIN 3. First, we can infer that an earlier report from ALTS on baseline colposcopic performance 24 underestimated its sensitivity because approximately a quarter of CIN 3 diagnosed in ALTS was probably incident. Second, future trials of pharmacotherapeutic agents to treat HPV infections must account for a subset of HPV infections that are associated with missed prevalent CIN 3; these missed cases will be diagnosed after the intervention and will be considered a treatment failure. Conversely, screening trials may underestimate the positive predictive values of tests if precautions are not taken to diagnose all prevalent disease.
